BRPI0312811A8 - monoetano sulfonato de 3-z-[1-(4-(n-((4-metil-piperazin-1-il)metilcarbonil)-n-metil-amino)anilino)-1-fenilmetileno]-6-metóxicarbonil-2-indolinona, seu uso, e composição farmacêutica - Google Patents

monoetano sulfonato de 3-z-[1-(4-(n-((4-metil-piperazin-1-il)metilcarbonil)-n-metil-amino)anilino)-1-fenilmetileno]-6-metóxicarbonil-2-indolinona, seu uso, e composição farmacêutica Download PDF

Info

Publication number
BRPI0312811A8
BRPI0312811A8 BRPI0312811A BR0312811A BRPI0312811A8 BR PI0312811 A8 BRPI0312811 A8 BR PI0312811A8 BR PI0312811 A BRPI0312811 A BR PI0312811A BR 0312811 A BR0312811 A BR 0312811A BR PI0312811 A8 BRPI0312811 A8 BR PI0312811A8
Authority
BR
Brazil
Prior art keywords
methyl
indolinone
anilino
pharmaceutical composition
piperazin
Prior art date
Application number
BRPI0312811A
Other languages
English (en)
Other versions
BRPI0312811B8 (pt
BR0312811A (pt
BRPI0312811B1 (pt
Inventor
Hilberg Frank
Jürgen Roth Gerald
Linz Günter
Sieger Peter
Bock Thomas
Rall Werner
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30469050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0312811(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of BR0312811A publication Critical patent/BR0312811A/pt
Publication of BRPI0312811A8 publication Critical patent/BRPI0312811A8/pt
Publication of BRPI0312811B1 publication Critical patent/BRPI0312811B1/pt
Publication of BRPI0312811B8 publication Critical patent/BRPI0312811B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"monoetano sulfonato de 3-z-[1-(4-(n-((4-metil piperazin-1-il) metil carbonil)-n-metil-amino) anilino)-1-fenil-metilenoi-6-metóxi carbonil-2-indolinona e seu uso como uma composição farmacêutica". a presente invenção refere-se ao composto monoetano sulfonato de 3-z-[1-(4-(n-((4-metil piperazin-1-il) metil carbonil)-n-metil amino) anilino)-1-fenil metileno]-6-metóxi carbonil-2-indolinona de fórmula (i) e seu uso como uma composição farmacêutica.
BRPI0312811A 2002-07-24 2003-07-18 monoetano sulfonato de 3-z-[1-(4-(n-((4-metil-piperazin-1-il)metilcarbonil)-n-metil-amino)anilino)-1-fenilmetileno]-6-metóxicarbonil-2-indolinona, seu uso, e composição farmacêutica BRPI0312811B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10233500A DE10233500A1 (de) 2002-07-24 2002-07-24 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
DE10233500.1 2002-07-24
PCT/EP2003/007822 WO2004013099A1 (en) 2002-07-24 2003-07-18 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition

Publications (4)

Publication Number Publication Date
BR0312811A BR0312811A (pt) 2005-04-19
BRPI0312811A8 true BRPI0312811A8 (pt) 2019-01-02
BRPI0312811B1 BRPI0312811B1 (pt) 2019-03-12
BRPI0312811B8 BRPI0312811B8 (pt) 2021-05-25

Family

ID=30469050

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0312811A BRPI0312811B8 (pt) 2002-07-24 2003-07-18 monoetano sulfonato de 3-z-[1-(4-(n-((4-metil-piperazin-1-il)metilcarbonil)-n-metil-amino)anilino)-1-fenilmetileno]-6-metóxicarbonil-2-indolinona, seu uso, e composição farmacêutica

Country Status (36)

Country Link
US (2) US7119093B2 (pt)
EP (2) EP2386543A1 (pt)
JP (1) JP5039279B2 (pt)
KR (1) KR101145691B1 (pt)
CN (1) CN100351235C (pt)
AR (2) AR040662A1 (pt)
AT (1) ATE551322T1 (pt)
AU (1) AU2003254376B2 (pt)
BR (1) BRPI0312811B8 (pt)
CA (1) CA2493310C (pt)
CY (1) CY1112916T1 (pt)
DE (1) DE10233500A1 (pt)
DK (1) DK1527047T3 (pt)
EA (1) EA008684B1 (pt)
EC (1) ECSP055571A (pt)
EG (1) EG24562A (pt)
ES (1) ES2384968T3 (pt)
HK (1) HK1078851A1 (pt)
HR (1) HRP20050070B1 (pt)
IL (2) IL166405A0 (pt)
ME (1) ME00353B (pt)
MX (1) MXPA04012785A (pt)
MY (1) MY136883A (pt)
NO (1) NO330486B1 (pt)
NZ (1) NZ538367A (pt)
PE (1) PE20040704A1 (pt)
PL (1) PL223758B1 (pt)
PT (1) PT1527047E (pt)
RS (1) RS52283B (pt)
SA (1) SA03240446B1 (pt)
SI (1) SI1527047T1 (pt)
TW (1) TWI285635B (pt)
UA (1) UA78352C2 (pt)
UY (1) UY27904A1 (pt)
WO (1) WO2004013099A1 (pt)
ZA (1) ZA200409814B (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
EP1870400A1 (en) * 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
AU2008265104B2 (en) 2007-06-21 2013-09-12 Janssen Pharmaceutica Nv Indolin-2-ones and aza-indolin-2-ones
UY31506A1 (es) * 2007-12-03 2009-08-03 Derivados de indolinona y procedimiento para su preparacion
ES2658091T3 (es) * 2007-12-03 2018-03-08 Boehringer Ingelheim International Gmbh Procedimiento para la fabricación de un derivado de indolinona
LT2985025T (lt) * 2008-06-06 2018-04-10 Boehringer Ingelheim International Gmbh Farmacinis derinys
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
US20110301177A1 (en) 2008-06-06 2011-12-08 Boehringer Ingelheim International Gmbh Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
EP2387401A1 (en) 2009-01-14 2011-11-23 Boehringer Ingelheim International GmbH Method for treating colorectal cancer
US8802384B2 (en) * 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
EP2429520A1 (en) 2009-05-14 2012-03-21 Boehringer Ingelheim International GmbH New combination therapy in treatment of oncological and fibrotic diseases
US20120136004A1 (en) * 2009-05-14 2012-05-31 Boehringer Ingelheim International Gmbh New combination therapy in treatment of cancer and fibrotic diseases
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
WO2012068441A2 (en) 2010-11-19 2012-05-24 Ratiopharm Gmbh Intedanib salts and solid state forms thereof
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
EP2875020B1 (en) 2012-07-19 2017-09-06 Boehringer Ingelheim International GmbH Process for the preparation of a fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one
CA2890207A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
CA2890346A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
US10980804B2 (en) 2013-01-18 2021-04-20 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US20140350022A1 (en) * 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
WO2015009889A1 (en) * 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
CA3172586A1 (en) 2013-07-31 2015-02-05 Avalyn Pharma Inc. Aerosol imatininb compounds and uses thereof
US20170114323A1 (en) * 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
CN106008308A (zh) * 2015-03-13 2016-10-12 正大天晴药业集团股份有限公司 尼达尼布乙磺酸盐结晶
WO2016178064A1 (en) 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
CN105126909B (zh) * 2015-07-13 2018-01-23 淮海工学院 固载钯催化剂在4‑苯乙炔基‑3‑硝基苯甲酸甲酯合成中的应用
CN105001143A (zh) * 2015-07-24 2015-10-28 南京正大天晴制药有限公司 一种制备高纯度乙磺酸尼达尼布的方法
CN106432042A (zh) * 2015-08-13 2017-02-22 南京华威医药科技开发有限公司 尼达尼布乙磺酸水合物的药物新晶型
WO2017077551A2 (en) * 2015-11-03 2017-05-11 Mylan Laboratories Limited An amorphous nintedanib esylate and solid dispersion thereof
CZ2016104A3 (cs) * 2016-02-24 2017-09-06 Zentiva, K.S. Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy
JP2019511547A (ja) * 2016-04-13 2019-04-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 結腸直腸癌を治療するためのニンテダニブ、トリフルリジンおよびチピラシルの医薬組合せ
EP3246029A1 (en) 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
CN109415314A (zh) * 2016-05-19 2019-03-01 上海诚妙医药科技有限公司 尼达尼布的新晶型及其制备方法及其用途
WO2017203027A1 (en) 2016-05-27 2017-11-30 Boehringer Ingelheim International Gmbh Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
JP2019523225A (ja) 2016-06-01 2019-08-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ニンテダニブおよびピルフェニドンによる治療開始を決定するためのｅｃｍバイオマーカーの使用
ITUA20164213A1 (it) 2016-06-08 2017-12-08 Olon Spa Polimorfo di nintedanib
US10772885B2 (en) 2016-09-26 2020-09-15 Reyoung (Suzhou) Biology Science & Technology Co., Ltd. Composition for treating ocular diseases and methods of usage and making
JP2019536812A (ja) 2016-12-12 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ
US10981896B2 (en) * 2017-03-02 2021-04-20 Board Of Regents, The University Of Texas System Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase
CN110072849A (zh) * 2017-03-14 2019-07-30 新源生物科技股份有限公司 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型
TWI632133B (zh) * 2017-03-15 2018-08-11 新源生物科技股份有限公司 ３－ｚ－［１－（４－（ｎ－（（４－甲基－哌嗪－１－基）－甲羰基）－ｎ－甲基－胺基）－苯胺基）－１－苯基－亞甲基］－６－甲氧羰基－２－吲哚啉酮的晶型
TWI676617B (zh) * 2017-03-15 2019-11-11 新源生物科技股份有限公司 3-z-[1-(4-(n-((4-甲基-呱嗪-1-基)-甲羰基)-n-甲基-胺基)-苯胺基)-1-苯基-亞甲基]-6-甲氧羰基-2-吲哚啉酮的晶型
CN110573161A (zh) 2017-03-28 2019-12-13 勃林格殷格翰国际有限公司 用于治疗肌营养不良的方法的尼达尼布
WO2019048974A1 (en) * 2017-09-06 2019-03-14 Glenmark Pharmaceuticals Limited PROCESS FOR PREPARING NINTEDANIB
IL273169B2 (en) 2017-10-23 2024-05-01 Boehringer Ingelheim Int A new combination of active substances for the treatment of advanced lymphoid interstitial lung diseases
JP7382317B2 (ja) 2017-11-17 2023-11-16 フェルミオン オサケ ユキチュア ニンテダニブを製造するための中間体として公知の２－インドリノン誘導体の合成
TW201938158A (zh) 2018-03-07 2019-10-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
CN116808044A (zh) 2018-06-15 2023-09-29 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
CN109988094B (zh) * 2019-04-29 2020-04-14 石药集团中奇制药技术（石家庄）有限公司 一种乙磺酸尼达尼布的制备方法
TW202133844A (zh) 2019-12-04 2021-09-16 瑞士商愛杜西亞製藥有限公司 吖丁啶lpa1受體拮抗劑與抗纖維化藥劑之組合
JP2023519600A (ja) 2020-04-01 2023-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維性状態の治療におけるバイオマーカーの使用
US20230181582A1 (en) 2020-05-22 2023-06-15 Qx Therapeutics Inc. Compositions and methods for treating lung injuries associated with viral infections
EP4178555A4 (en) * 2020-08-07 2024-08-07 Bdr Lifesciences Private Ltd IMPROVED HIGHLY EFFECTIVE PROCESS FOR THE PRODUCTION OF NINTEDANIB AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
CN111848490B (zh) * 2020-08-24 2021-09-24 江西国药有限责任公司 一种高纯度乙磺酸尼达尼布的制备方法
CN113024439A (zh) * 2021-03-28 2021-06-25 郑州大学 尼达尼布乙磺酸盐新晶型ⅰ的制备
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
AU2022443590A1 (en) 2022-02-28 2024-10-17 Nuformix Technologies Limited Compositions and methods for treatment of idiopathic pulmonary fibrosis
WO2024037982A1 (en) 2022-08-16 2024-02-22 Boehringer Ingelheim International Gmbh Pharmaceutical formulations of nintedanib for intraocular use
KR20240042322A (ko) 2022-09-23 2024-04-02 삼아제약 주식회사 티로신 키나제 저해제를 유효성분으로 하는 약제학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB395546A (en) 1931-10-12 1933-07-20 Robert Pauli Scherer Method of and apparatus for making capsules
US2720463A (en) 1950-11-17 1955-10-11 American Cyanamid Co Gelatin capsule casting composition preparation
US2870062A (en) 1956-04-27 1959-01-20 Scherer Corp R P Gelatin composition for capsules
DE3579384D1 (de) 1984-07-24 1990-10-04 Scherer Gmbh R P Oxytetracyclin-hc1-weichgelatinekapseln und verfahren zu ihrer herstellung.
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
SI1212320T1 (en) * 1999-08-23 2005-10-31 Solvay Pharmaceuticals B.V. Phenylpiperazines as serotonin reuptake inhibitors
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
DE19949209A1 (de) * 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10117204A1 (de) * 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel

Also Published As

Publication number Publication date
AU2003254376A1 (en) 2004-02-23
ZA200409814B (en) 2006-02-22
PL372996A1 (en) 2005-08-08
US20060258681A1 (en) 2006-11-16
JP5039279B2 (ja) 2012-10-03
EA008684B1 (ru) 2007-06-29
UY27904A1 (es) 2004-02-27
CN100351235C (zh) 2007-11-28
NO330486B1 (no) 2011-04-26
EP1527047A1 (en) 2005-05-04
KR20050042139A (ko) 2005-05-04
MY136883A (en) 2008-11-28
US7119093B2 (en) 2006-10-10
AU2003254376B2 (en) 2010-06-17
DK1527047T3 (da) 2012-07-16
IL166405A0 (en) 2006-01-15
CN1671660A (zh) 2005-09-21
BRPI0312811B8 (pt) 2021-05-25
TW200409754A (en) 2004-06-16
DE10233500A1 (de) 2004-02-19
SI1527047T1 (sl) 2012-07-31
ATE551322T1 (de) 2012-04-15
JP2005535684A (ja) 2005-11-24
US20040176392A1 (en) 2004-09-09
ES2384968T3 (es) 2012-07-16
HRP20050070B1 (hr) 2013-09-30
KR101145691B1 (ko) 2012-05-25
SA03240446B1 (ar) 2007-07-31
RS52283B (sr) 2012-10-31
BR0312811A (pt) 2005-04-19
EG24562A (en) 2009-10-25
UA78352C2 (uk) 2007-03-15
PL223758B1 (pl) 2016-10-31
TWI285635B (en) 2007-08-21
RS20050046A (en) 2007-09-21
CA2493310A1 (en) 2004-02-12
NO20050985L (no) 2005-02-23
EA200500146A1 (ru) 2005-08-25
PE20040704A1 (es) 2004-11-29
CA2493310C (en) 2011-01-18
HK1078851A1 (en) 2006-03-24
ECSP055571A (es) 2005-04-18
BRPI0312811B1 (pt) 2019-03-12
PT1527047E (pt) 2012-06-28
WO2004013099A1 (en) 2004-02-12
AR094217A2 (es) 2015-07-15
HRP20050070A2 (en) 2005-12-31
MXPA04012785A (es) 2005-06-08
EP1527047B1 (en) 2012-03-28
EP2386543A1 (en) 2011-11-16
CY1112916T1 (el) 2016-04-13
IL166405A (en) 2009-11-18
ME00353B (me) 2011-10-10
AR040662A1 (es) 2005-04-13
MEP53708A (en) 2011-05-10
NZ538367A (en) 2008-01-31

Similar Documents

Publication Publication Date Title
BRPI0312811A8 (pt) monoetano sulfonato de 3-z-[1-(4-(n-((4-metil-piperazin-1-il)metilcarbonil)-n-metil-amino)anilino)-1-fenilmetileno]-6-metóxicarbonil-2-indolinona, seu uso, e composição farmacêutica
RS51013B (sr) Indolinon supstituisan na poziciji 6, njegovo dobijanje i njegova upotreba kao leka
UY26943A1 (es) Derivados de piridina
ATE333453T1 (de) Mannich base prodrugs von 3-(pyrrol-2- ylmethylidene)-2-indolinon derivate und deren verwendung als protein kinase inhibitoren
ATE449090T1 (de) Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
EA200700188A1 (ru) Производные замещенного 2-алкилхиназолинона как ингибиторы parp
NO20091892L (no) Krystallinsk form av (3S)-3-(N-(N`-(2-tert-butylfenyl)oksamyl) alaninyl)amino-5-(2`,3`,5`,6`-tetrafluorfenoksy)-4 oksopentanoisk syre
BRPI0408347A (pt) derivados de pirimidina
ATE394383T1 (de) Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren
ATE490253T1 (de) Synthese von 5-substituierten 7-azaindolen und 7- azaindolinen
EA200301100A1 (ru) Новые фталазиноны
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
DE60336266D1 (de) Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl-piperazinderivate und deren verwendung als neurokinin antagonisten
DE60005401D1 (de) Carboxamidderivate von pyrrolidine und piperidine als urotensin-ii rezeptorantagonisten
ATE342265T1 (de) Neue prodrugs von 1-methyl-2-(4- amidinophenylaminomethyl)-benzimidazol-5-yl- carbonsäure-(n -2-pyridil-n-2- hydroxycarbonylethyl)-amid, ihre herstellung und ihre verwendung als arzneimittel
MXPA05009282A (es) Derivados de anilina sustituidos.
ATE355265T1 (de) Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
EA200301101A1 (ru) Производные пиперазина и их применение в качестве ингибиторов pde4
HRP20040360B1 (hr) Linearni baziäśni spojevi koji djeluju kao antagonisti nk2 i njihove formulacije
ATE301463T1 (de) Pharmazeutische zusammensetzungen enthaltend 17alpha-furanylester von 17beta-carbothioat androstanderivaten und einen muskarinrezeptorantagonist
EA200501299A1 (ru) Замещенные производные анилина
DE60317709D1 (de) Substituierte 1-piperidin-3-yl-4-piperidin-4-yl-piperazin-derivate und ihre verwendung als neurokinin-antagonisten
DE59901563D1 (de) N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung
TH100980B (th) 3-z-[1-(4-(n-((4-เมทิล-ไพเพอราซิน-1-อิล)-เมทิลคาร์บอนิล)-n-เมทิล-อะมิโน)-แอนิลิโน)-1-เฟนิล-เมทิลีน]-6-เมทอกซีคาร์บอนิล-2-อินโคลิโนน-โมโนอีเทนซัลโฟเนต และการใช้สารนั้นเป็นสารผสมทางเภสัชกรรม

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/03/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/07/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.012371/2021-48 ORIGEM: JUIZO FEDERAL DA 31A VF DO RIO DE JANEIRO (TRF2) PROCESSO NO: 5126121-81.2021.4.02.5101 NULIDADE DE PATENTE DE INVENCAO AUTOR: SUN FARMACEUTICA DO BRASIL LTDA REU(S): BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG E BOEHRINGER INGELHEIM INTERNATIONAL GMBH E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI